For US Healthcare Professionals
I am a:
IN ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PsO)
~8 out of 10 PsO patients continued therapy through 5 years1*
No conclusions regarding clinical efficacy or safety can be drawn.
*Year 5 represents Week 252.
†Includes patients randomized to TREMFYA® and to placebo at baseline who crossed over to receive TREMFYA® at Week 16.
‡Includes subjects who were randomized but not treated.
§Includes pregnancy, noncompliance with study drug, and/or protocol violation.
Reference: 1. Data on file. Janssen Biotech, Inc.
IN ADULTS WITH MODERATE TO SEVERE PLAQUE PsO
